Therapeutic strategies aimed at reducing uremic toxin levels, such as the use of intestinal adsorbents or gut microbiota modulators (e.g., probiotics), may help mitigate macrophage-driven vascular inflammation
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 261,46 per year only 21,79 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
DEXA was originally developed to measure bone density, but it also became the gold standard for body composition analysis
By extending earlier preclinical work on GLP-1 receptor agonists and alcohol intake to a task that directly assesses the subjective effects of alcohol, these findings provide important context for interpreting clinical observations of reduced drinking behavior among individuals receiving GLP-1 receptor-based therapies
People on GLP-1 agonists typically lose lean body mass in addition to fat, but it is not yet clear whether this leads to functional decline due to muscle loss or fractures due to bone loss
Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, et al
